Danyan Cao

516 total citations
23 papers, 408 citations indexed

About

Danyan Cao is a scholar working on Molecular Biology, Hematology and Organic Chemistry. According to data from OpenAlex, Danyan Cao has authored 23 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 8 papers in Hematology and 5 papers in Organic Chemistry. Recurrent topics in Danyan Cao's work include Protein Degradation and Inhibitors (13 papers), Multiple Myeloma Research and Treatments (8 papers) and Ubiquitin and proteasome pathways (6 papers). Danyan Cao is often cited by papers focused on Protein Degradation and Inhibitors (13 papers), Multiple Myeloma Research and Treatments (8 papers) and Ubiquitin and proteasome pathways (6 papers). Danyan Cao collaborates with scholars based in China, United States and Poland. Danyan Cao's co-authors include Bing Xiong, Jingkang Shen, Yanlian Li, Xin Wang, Jian Li, Ze‐Hong Miao, Ying-Qing Wang, Danqi Chen, Naixia Zhang and Yechun Xu and has published in prestigious journals such as Chemical Communications, Journal of Medicinal Chemistry and Molecules.

In The Last Decade

Danyan Cao

22 papers receiving 404 citations

Peers

Danyan Cao

HEMAT

ONCOL

CTM

Jin-Yi Zhu United States

Jonathan Pollock United States

Emma J. Jones United Kingdom

Peter G. K. Clark United Kingdom

Nunzio Sciammetta United States

Maryanna E. Lanning United States

Darren J. Mitchell United Kingdom

Diego García Jiménez Italy

Elena Ho United States

Victoria G. Klein United States

Jin-Yi Zhu United States

Danyan Cao

357 ×1.0

148 ×1.0

HEMAT

82 ×1.1

54 ×1.5

ONCOL

48 ×1.5

CTM

Citations per year, relative to Danyan Cao Danyan Cao (= 1×) peers Jin-Yi Zhu

Countries citing papers authored by Danyan Cao

Since Specialization

Citations

This map shows the geographic impact of Danyan Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danyan Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danyan Cao more than expected).

Fields of papers citing papers by Danyan Cao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danyan Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danyan Cao. The network helps show where Danyan Cao may publish in the future.

Co-authorship network of co-authors of Danyan Cao

This figure shows the co-authorship network connecting the top 25 collaborators of Danyan Cao. A scholar is included among the top collaborators of Danyan Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danyan Cao. Danyan Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cao, Danyan. (2025). WTAP-mediated m6A regulation in digestive system cancers: from molecular mechanisms to therapeutic strategies. American Journal of Cancer Research. 15(8). 3661–3677. 1 indexed citations

Wu, Tingting, Danyan Cao, Yali Chen, et al.. (2025). Multi-Water Bridges Enable Design of BET BD1-Selective Inhibitors for Pancreatic Cancer Therapy. Journal of Medicinal Chemistry. 68(5). 5719–5735. 4 indexed citations

Yang, Yueyue, Haiyang Zhong, Yanlian Li, et al.. (2025). Design of Selective BRD4 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease. Journal of Medicinal Chemistry. 68(5). 5257–5274. 2 indexed citations

Chen, Chao, et al.. (2025). trans-Ge/B 1,1-Hydroboration of Alkynylgermanes with 9-BBN. Organic Letters. 27(16). 4079–4084. 1 indexed citations

Liu, Yu‐Chao, et al.. (2025). Catalytic acceptorless dehydrogenation of alcohols using cobalt(i) pincer complexes supported by a P–GeH–P ligand. Chemical Communications. 61(38). 6917–6920.

Mou, Jie, Huijie Zhang, Yanlian Li, et al.. (2024). Structure-Based Rational Design and Evaluation of BET-Aurora Kinase Dual-Inhibitors for Treatment of Cancers. Journal of Medicinal Chemistry. 68(2). 1344–1364. 5 indexed citations

Chen, Xuetao, Tingting Wu, Rujun Xu, et al.. (2023). Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis. European Journal of Medicinal Chemistry. 265. 116080–116080. 10 indexed citations

Song, Lingyu, Jiawen Cao, Zhiyan Du, et al.. (2023). Screening and optimization of phage display cyclic peptides against the WDR5 WBM site. RSC Medicinal Chemistry. 14(10). 2048–2057. 2 indexed citations

Cao, Danyan, Fanying Meng, Zijian Zhang, et al.. (2023). Discovery of 1H-Imidazo[4,5-b]pyridine Derivatives as Potent and Selective BET Inhibitors for the Management of Neuropathic Pain. Journal of Medicinal Chemistry. 66(13). 8725–8744. 9 indexed citations

10.

Li, Na, Hong Yang, Ke Liu, et al.. (2022). Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors. Journal of Medicinal Chemistry. 65(13). 9459–9477. 20 indexed citations

11.

Liu, Yuwei, Mengzhu Xue, Danyan Cao, et al.. (2021). Multi-omics characterization of WNT pathway reactivation to ameliorate BET inhibitor resistance in liver cancer cells. Genomics. 113(3). 1057–1069. 5 indexed citations

12.

Zhang, Zhuqing, Xiaowei Xu, Danyan Cao, et al.. (2021). Structure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy. Journal of Medicinal Chemistry. 64(22). 16650–16674. 25 indexed citations

13.

Hu, Jianping, Changqing Tian, Yanlian Li, et al.. (2019). Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors. Journal of Medicinal Chemistry. 62(18). 8642–8663. 31 indexed citations

14.

Zhang, Zhuqing, Hong Yang, Danyan Cao, et al.. (2019). Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 against Acute Myeloid Leukemia. Journal of Medicinal Chemistry. 62(11). 5414–5433. 21 indexed citations

15.

Chen, Danqi, Yuehong Chen, Fulin Lian, et al.. (2018). Fragment-based drug discovery of triazole inhibitors to block PDEδ-RAS protein-protein interaction. European Journal of Medicinal Chemistry. 163. 597–609. 22 indexed citations

16.

Hu, Jianping, Ying-Qing Wang, Yanlian Li, et al.. (2018). Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups. European Journal of Medicinal Chemistry. 150. 156–175. 19 indexed citations

17.

Hu, Jianping, Ying-Qing Wang, Yanlian Li, et al.. (2017). Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor. European Journal of Medicinal Chemistry. 137. 176–195. 30 indexed citations

18.

Ren, Jing, Jian Li, Yueqin Wang, et al.. (2014). Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization. Bioorganic & Medicinal Chemistry Letters. 24(11). 2525–2529. 17 indexed citations

19.

Yang, Min, Hong‐Chun Liu, Danyan Cao, et al.. (2014). Multi-substituted 8-aminoimidazo[1,2-a]pyrazines by Groebke–Blackburn–Bienaymé reaction and their Hsp90 inhibitory activity. Organic & Biomolecular Chemistry. 13(5). 1531–1535. 20 indexed citations

20.

Cao, Danyan, Tiantian Chen, Ying-Qing Wang, et al.. (2013). Fragment-Based Drug Discovery of 2-Thiazolidinones as Inhibitors of the Histone Reader BRD4 Bromodomain. Journal of Medicinal Chemistry. 56(10). 3833–3851. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact